biostudies-literatureUnknown81(5)Cid MCKiniksa Pharmaceuticals, Ltd.<h4>Objectives</h4>Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission.<h4>Methods</h4>This phase 2, double-blind, placebo-controlled trial enrolled patients with biopsy-confirmed or imaging-confirmed giant cell arteritis in 50 centres (North America, Europe, Australia). Active disease within 6 weeks of baseline was required for inclusion. Patients in glucocorticoid-induced remission were randomly assigned (3:2 ratio) to mavrilimumab 150 mg or placebo injected subcutaneously every 2 weeks. Both groups received a 26-week prednisone taper. The primary outcome was time to adjudicated flare by week 26. A prespecified secondary efAnnals of the rheumatic diseases653-661https://www.ebi.ac.uk/biostudies/studies/S-EPMC8995812biostudies-literatureEfficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.PMC8995812Salvarani CDagna LTrapnell BCUnizony SHZhou TMolloy EPupim LKPL-301-C001 InvestigatorsCid MCBrouwer EWicks IPaolini JFDasgupta BWarrington KJBlockmans DHellmich BSamant MfalseEfficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.<h4>Objectives</h4>Granulocyte-macrophage colony-stimulating factor (GM-CSF) is implicated in pathogenesis of giant cell arteritis. We evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission.<h4>Methods</h4>This phase 2, double-blind, placebo-controlled trial enrolled patients with biopsy-confirmed or imaging-confirmed giant cell arteritis in 50 centres (North America, Europe, Australia). Active disease within 6 weeks of baseline was required for inclusion. Patients in glucocorticoid-induced remission were randomly assigned (3:2 ratio) to mavrilimumab 150 mg or placebo injected subcutaneously every 2 weeks. Both groups received a 26-week prednisone taper. The primary outcome was time to adjudicated flare by week 26. A prespecified secondary ef2022-01-01T00:00:00Z2022 May2026-06-07T07:33:42.426Z2025-04-05T07:15:32.428ZS-EPMC89958123526432110.1136/annrheumdis-2021-221865